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THE EFFECTS OF XANTHIGENTM SUPPLEMENTATION ON BODY 
COMPOSITION, SERUM MARKERS OF THE METABOLIC SYNDROME, AND 
HEPAPTIC ENZYME LEVELS IN AN OBESE POPULATION  
 
   XanthigenTM [100 mg brown seaweed extract (0.8 % fucoxanthin) and 100 mg 
pomegranate seed oil (70 % punicic acid)] has been shown to significantly reduce body 
fat, liver fat, and improve serum markers of liver function in obese females. Twenty-nine 
participants were matched for age, gender, and body fat percentage and randomized into 
either a XanthigenTM group or a placebo group. For 16-weeks, participants were asked to 
consume a reduced calorie diet while supplementing their diet with their respective pills 
three times per day. Data were analyzed using multivariate ANOVA with repeated 
measures and presented as mean ± standard deviation. While most participants saw 
weight loss, body fat percentage did not significantly change, indicating that weight loss 
was from both fat mass and lean mass. Significant changes were seen in serum levels of 
alkaline phosphatase (ALP), alanine transaminase (ALT), total protein, and albumin. The 
changes in both the placebo and Xanthigen groups were similar, however. No significant 
changes were seen in other serum markers, but there was a trend for a reduction in 
triglycerides with a statistical trend for a greater decrease in the Xanthigen group. While 
both placebo and Xanthigen groups experienced weight loss and reduced liver enzyme 
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Chapter 1: Problem Statement 
Over the past two decades in the United States, the incidence of overweight and 
obesity has been a rising trend (Center for Disease Control and Prevention [CDC], 
2011a). Although the dramatic increase in these numbers has begun to diminish, more 
than half of the states in the U.S. had a twenty-five percent or greater obesity rate as of 
2009 (CDC, 2011a). Furthermore, nine states, mostly in the south, have obesity rates of 
greater than thirty percent (CDC, 2011a). In addition to the large number of Americans 
that are obese, thirty-four percent of all Americans are overweight (CDC, 2011a). The 
problem created by this great prevalence of overweight and obesity is that these 
individuals are at a greater risk for the development of other diseases. According to the 
National Heart, Lung, and Blood Institutes, overweight and obesity lead to an increase in 
the morbidity rate of diseases such as hypertension, Type II diabetes, coronary heart 
disease, stroke, various forms of cancer, and many other dangerous diseases (National 
Health Institutes, 1998; Pi-Sunyer, 2002). Along with the increasing morbidity rates, 
individuals with a body-mass index (BMI) greater than thirty have a 50 to 100 times 
greater risk of all-cause mortality, especially due to cardiovascular disease (National 
Health Institutes, 1998; Pi-Sunyer, 2002).  
 Because overweight and obesity are such common problems, many studies have 
attempted to determine appropriate ways to combat them. A proper diet and physical 
activity are two of the main factors in the cure for obesity, but often times they are not 
enough. Since healthy diet and regular physical activity may not be practical options for 
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all Americans, many nutritional supplements have entered the market that promise to 
promote weight loss. In recent years, a nutritional supplement called Xanthigen has been 
produced and testing has begun on its anti-obesity effects. Abidov and colleagues 
(Abidov, Ramazanov, Seifulla, & Grachev, 2010) conducted studies on obese women 
using Xanthigen supplementation to determine the physiological changes elicited by the 
supplement. This study reported that Xanthigen was well tolerated, reduced body weight, 
body fat, and waist circumference. Additionally, all groups had a reduction in serum 
triglycerides and in liver enzymes. Xanthigen has proven to be safe and effective thus far, 
quite possibly providing Americans with a “quick fix” to their weight problems.  
 Because Xanthigen is new to the market, very little testing has been completed on 
this supplement. Abidov and his fellow researchers (2010) used only obese women in 
their study, and thus present results are very exclusive to a certain population. To gain 
more knowledge about the Xanthigen supplement, a broader study must be done 
including men and women of broader age categories. In the study at hand, the effects of 
Xanthigen supplementation on obese men and women was assessed by examining body 
composition, lipid levels [triglycerides, high-density lipoproteins (HDL), low-density 
lipoproteins (LDL), and total cholesterol levels], liver enzymes [alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), and γ-glutamyltransferase (GGT)], and glucose 
and insulin concentrations in the blood. In this study, obesity was defined as individuals 
with a BMI of greater than 30 kg/m2. This particular study was a 16-week double blind 
experiment. It was hypothesized that with Xanthigen supplementation, body composition 
would improve (body fat percentage decrease), lipid levels improve (triglyceride and 
LDL decrease, but HDL increase), liver enzymes levels improve (decrease), and glucose 
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concentrations would improve (decrease). Many of the results of this study are contrary 
to Abidov’s study (2010), thus leading to new potential studies to further elucidate the 
mechanism and effectiveness of Xanthigen supplementation.  
Chapter 2: Literature Review 
Obesity  
 Over the past two decades, obesity has become a major health concern worldwide. 
According to the CDC, adult obesity has been defined as a body-mass index (BMI) of 
greater than 30 kg/m2 (CDC, 2011b). Since the 1980s, obesity has reached epidemic 
proportions worldwide. In the United States alone, almost one hundred million people 
suffer from the effects of overweight and obesity (National Health Institutes, 1998; Pi-
Sunyer, 2002). As of 2005, nearly one-third of all US adults were classified as obese 
(Baskin, Ard, Franklin, and Allison, 2005). The CDC reports that in 2009, 33 states 
reported 25% or greater obesity rates (CDC, 2011a). Additionally, nine states had obesity 
rates of 30% or greater (CDC, 2011a). Of these nine states, Mississippi held the highest 
obesity rate, with 34.4 percent of all Mississippians being obese (CDC, 2011a). It is 
predicted that by the year 2020, greater than 40% of men and greater than 43% of women 
will be considered obese (Ruhm, 2007). This great prevalence of obesity poses concerns 
for all.  
 Obesity is closely linked with many other diseases and higher mortality rates than 
what is seen in a normal, healthy population. Excessive body weight alone is linked with 
hypertension, type II diabetes mellitus, coronary heart disease, gallbladder disease, 
osteoarthritis, sleep apnea, respiratory problems, and some types of cancer (National 
Health Institutes, 1998; Pi-Sunyer, 2002). As BMI increases, blood pressure increases 
4 
 
proportionally (Must et al., 1999). According to the National Health Institutes (1998), 
between thirty and forty percent of all obese people have hypertension. These increases in 
blood pressure are also correlated with increases for the likelihood of stroke and coronary 
heart disease (National Health Institutes, 1998; Pi-Sunyer, 2002). Along with 
hypertension, obesity is also related to dyslipidemia. As is the case with blood pressure, 
serum lipid levels rise with weight gains. Obese persons see rises in total cholesterol, 
triglycerides, and LDL (National Health Institutes, 1998; Pi-Sunyer, 2002). Increases in 
obesity are often also linked to an increased death rate (Flegal, Graubard, Williamson, 
and Gail, 2005).  
 Another issue raised by the prevalence of obesity is the cost to care for those who 
are obese. Previously it was estimated that on an annual basis, obese individuals’ 
healthcare costs about $395 more than normal adults (Finklestein, Fiebelkom, and Wang, 
2003). This was an increase of about 36%. More recent numbers indicate that obesity 
costs approximately $732, or 37.4% more than adults of a healthy body weight. About 
5.3% of all medical spending is put towards obesity-related expenses. With these 
statistics, the monetary costs of overweight and obesity are quickly becoming rivals to the 
monetary costs of smoking (Finklestein et al, 2003).  
Lipids and Obesity  
 Like many other issues, obesity is strongly linked with dyslipidemia, including 
hypertriglyceridemia and hyperlipidemia. According to the American Heart Association 
(AHA, 2011), triglycerides are “the chemical form in which most fats exist in food as 
well as in the body.”  While normal triglyceride levels are considered less than 150 
mg/dl, someone with elevated triglycerides, or hypertriglyceridemia, will have over 200 
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mg/dl (AHA, 2011). Although there are five major families of lipoproteins, dyslipidemia 
primarily focuses on HDL, LDL, and total cholesterol. HDL is considered “good” 
cholesterol. To be protected against heart disease, one should have an HDL level of at 
least 60 mg/dl (AHA, 2011). A person whose HDL levels fall below 50 mg/dl (for 
women) or 40 mg/dl (for men), are considered to be at greater risk for heart disease 
(AHA, 2011). LDL is considered “bad” cholesterol. Optimal LDL levels are less than 100 
mg/dl, while high LDL levels reach above 130 mg/dl (AHA, 2011). For healthy 
individuals, total cholesterol should be less than 200 mg/dl (AHA, 2011). Any person 
with total cholesterol of greater than 200 mg/dl more than doubles their risk for heart 
disease (AHA, 2011).  
 It has been shown that among the obese, hypertriglyceridemia is almost two times 
more likely to occur than in the non-obese (Kaplan, 1989). “Obesity is probably the 
metabolic stressor most frequently associated with hypertriglyceridemia…” (Yuan, Al-
Shali, and Hegele, 2007). The combination of obesity and non-alcoholic fatty liver 
disease (NAFLD) also correlates with elevated triglycerides and low HDL levels (Yuan 
et al., 2007). Similarly, obesity is related to the metabolic syndrome. Features of the 
metabolic syndrome include elevated triglycerides and lowered HDL levels (Hardman, 
1999). The connecting factor here is lipoprotein lipase (LPL), which is the enzyme 
responsible for breaking down triglycerides (Hardman, 1999). With a dysfunction in 
LPL, triglycerides are not appropriately removed, and are rather dissociated (Hardman, 
1999). Parts of this dissociation, including free cholesterol, may be transferred to HDLs, 
thus changing their make-up (Hardman, 1999). According to Kannel and colleagues 
(1979), HDL seems to be the lipoprotein most strongly related to obesity (Kannel, 
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Gordon, and Castelli, 1979). As HDL levels have an inverse relationship with obesity, 
total cholesterol levels often have a positive correlation with obesity. As BMI increases, 
so does serum cholesterol levels (Brown et al., 2000).  
Liver Enzymes and Obesity   
 Elevated transaminase levels are often of concern when looking at obesity. Liver 
enzyme levels can be elevated for multiple reasons. Although alcoholic liver disease is 
often a cause of elevated transaminases, NAFLD can also be a major underlying cause of 
this problem (Palmer, 2004a; Palmer, 2004b). Alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST) are the known markers for hepatocellular injury 
(Kundle, Lazenby, Clements, and Abrams, 2005). In obese youth populations, NAFLD is 
considered the primary reason for elevated ALT (Burgert et al., 2006). It has been found 
that with NAFLD, elevated ALT is the most common liver abnormality (Kerner, et. al., 
2005). Elevated ALT levels often indicate liver damage and may be predictors of type 2 
diabetes mellitus (Burgert et al., 2006). Burgert and colleagues hypothesized that elevated 
ALT may be a cause of defective glucose and insulin metabolism, and increases in free-
fatty acids and triglycerides. 
NAFLD is defined as “a condition of fat accumulation in the liver in the absence 
of excessive alcohol consumption and any other specific causes of hepatic steatosis,” 
(Bellentani and Marino, 2008). Although not completely understood, NAFLD is clearly 
linked with insulin resistance, and may often accompany obesity, as well as type 2 
diabetes (Bellentani and Marino, 2008). According to publications in Arteriosclerosis, 
Thrombosis, and Vascular Biology , NAFLD affects an estimated 25% of the American 
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population (Kerner et al., 2005). Complications with NAFLD include a link to further, 
more damaging, and often fatal liver disease, as well as cardiovascular disease 
(Bellentani and Marino, 2008).  
Fucoxanthin  
Edible seaweeds are very nutritious and are often full of nutritional benefits such 
as fiber, nutrients, and some minerals (Yan, Chuda, Suzuki, and Nagata, 1999). 
Fucoxanthin is a carotenoid found in Undaria pinnatifida that has been researched for its 
anti-obesity effects. In a study done by Maeda and colleagues (2005), edible seaweed 
(fucoxanthin) was fed to rats and mice and this study anti-obesity effects of fucoxanthin. 
Obese mice given a diet supplemented with 2% fucoxanthin saw a great reduction in the 
weight of their white adipose tissue. Through the results of these studies, it was 
determined that an increase in heat production from oxidation of fats will produce less 
incidence of diabetes (Maeda etal, 2005).  
 Maeda and colleagues (2008) also found that fucoxanthin can produce effects 
that have yet to be found in other dietary seaweed carotenoids, including, anti-obesity and 
anti-diabetic effects.  Through multiple studies in rodents and cell cultures, Maeda et al. 
(2005, 2008) found fucoxanthin to be an upregulator of uncoupling protein-1 (UCP-1) 
(Maeda et al, 2005; Maeda et al, 2008). This being said, upregulating UCP-1 is the 
alteration that produces the desired anti-obesity results. Furthermore, the presence of 
UCP-1allows for uncoupling of cellular respiration, which promotes the usage of fatty 
acids, and therefore promotes resistance to obesity (Ricquier, 2005).   Fucoxanthin 
supplementation also led to an increase in docoshexaenoic acid (DHA) production, 
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which, in turn, led to an increase in the fat burning process of beta-oxidation (Maeda et 
al, 2008).  
Pomegranate Seed Oil   
Pomegranate seed oil (PSO) contains a type of conjugated linolenic acid (CLN) 
called punicic acid (Yamasaki et al., 2006). In this study from Yamasaki and colleagues, 
mice were fed different dosages of PSO to determine its immunological effects. Many 
changes in immunoglobin production were observed; and contrary to what might be 
expected, PSO supplementation resulted in increased triglycerides, but did not affect the 
weight of adipose tissue (Yamasaki, et. al., 2006). The conclusions of this study were that 
PSO supplementation modulates lipid metabolism and promotes immunoglobin 
production, possibly producing desirable effects (Yamasaki, et. al., 2006).  
 Similarly, Arao, Yotsumoto, Han, Nagao, and Yanagita (2004b) discovered other 
effects of CLN. Rather than investigating immunoglobins and triglycerides, Arao and 
colleagues examined the relationship between apolipoprotein B100 (ApoB100) secretion 
and human liver derived cells, known as HepG2 cells. The findings of this study indicate 
that: CLN has the ability to suppress apoB100 secretion in the liver through the 
suppression of triglyceride synthesis in HepG2 cells. In conclusion, Arao’s study stated 
the possibility of using 9c,11t,13c-CLN as a hypolipidemic component (Arao, Yotsumoto 
et al., 2004b). 
In a study similar to the Yamasaki study (2006), rats were used to investigate the 
dietary effects of CLNA on lipid metabolism (Arao, Wang et al., 2004a). In one group of 
rats, obesity-like effects were induced. When comparing the obese rats to another 
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“control” group, it was determined that triglyceride concentration in the liver was 
significantly lowered by a diet including CLN (Arao, Wang et al., 2004a). It was decided 
that this was due to the suppression of delta-9 desaturation (Arao, Wang et al., 2004a).  
These previously mentioned studies have shown that through many mechanisms, 
pomegranate seed oil may produce desirable results.  
Xanthigen  
 Although proper diet and regular exercise are simple solutions for obesity, lack of 
compliance often impairs their results. In recent years, researchers have combined the 
anti-obesity effects of fucoxanthin and the positive effects of pomegranate seed oil to 
create a dietary supplement that can safely and effectively treat obesity. Through this 
combination, Xanthigen was born.  
 Abidov and his colleagues (2010) studied Xanthigen and its effects during a 16-
week, double-blind study on obese, premenopausal women. To do so, the Abidov 
research team recruited obese, premenopausal, non-diabetic women presenting with or 
without NAFLD (Abidov et al., 2010). A group of 72 women with NAFLD participated, 
while a group of 38 with normal liver fat also participated. The NAFLD group was split 
into two groups of 36, one control group and one Xanthigen group. NLF participants 
were also split into two equal groups (n=19), with one control group and one Xanthigen 
group. Another group of 41 women diagnosed with NAFLD was used specifically to 
measure changes in resting energy expenditure (REE). REE groups were further 
subdivided into: a placebo group, a Xanthigen-200/0.8 mg group, a Xanthigen-400/1.6 
mg group, a Xanthigen-600/2.4 mg group, a Xanthigen-1000/4 mg group, a fucoxanthin-
1.6 mg group, a fucoxanthin-2.4 mg group, a fucoxanthin-4.0 mg group, a fucoxanthin-
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8.0 mg group, a PSO-1500 mg group, and a PSO-2000 mg group. All food was provided 
to the participants throughout the duration of the study and their diets were restricted to 
1800 calories. Respective supplements were to be taken three times a day 15-30 minutes 
before each meal. A visit was required three times per week for measures to be taken.  
 Total weight and body fat were measured upon beginning the trial. Dual-energy 
X-ray absorptiometry was used to analyze body fat content. Liver fat content was 
quantified using proton magnetic resonance spectroscopy. Resting energy expenditure 
was measured using indirect calorimetry. Blood samples were taken and analyzed for 
ALT, AST, GGT, c-reactive protein (CRP), and triglycerides.  
 In the end, it was determined that Xanthigen and both of its components were 
well tolerated by all participants with no adverse effects reported. In this population, a 10 
pound or greater reduction in body weight was seen in groups supplemented with 
Xanthigen (Abidov et al, 2010). Although the placebo groups also lost weight, the 
Xanthigen supplemented group lost significantly more weight than did those participants 
who were given the placebo. Along with body weight improvements, body fat and, 
incidentally, liver fat percentages were also decreased. When looking at body fat and 
liver fat percentages, the placebo group saw no changes from the beginning of the study 
to the end. As might be expected due to the decrease in body weight, waist circumference 
also decreased in the Xanthigen supplemented group. The placebo group saw little to no 
changes in their waist circumference measures. Although serum triglyceride levels were 
reduced, they were not reduced significantly versus the control group except in the 
NAFLD group, where significant reduction was seen. Liver enzyme levels improved, as 
did C-reactive protein levels. These levels were significant compared to the placebo 
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groups. At certain concentrations, REE was significantly increased. Ultimately, Abidov 
and his colleagues (2010) determined that Xanthigen-600/2.4 was the best combination 
that safely produced many desired results to help combat overweight and obesity.  
 The study at hand sought to determine the effects of Xanthigen supplementation 
on an obese population. Through a 16-week, double-blind study, many changes were 
examined. It was expected that body composition, specifically body fat percentage, blood 
lipids, including triglycerides, HDL levels, LDL levels, and total cholesterol, certain liver 
enzymes, and glucose concentrations would all improve. Although Xanthigen 
supplementation was the most important factor in weight loss, participants were also 
placed on slightly restricted calorie diets to combat this confounding variable as much as 
possible. This being said, exercise still played a small role as another confounding 
variable that was monitored. 
Chapter 3: Methodology  
This study was a modified replication of Abidov and his colleagues’ original 
study on Xanthigen supplementation (2010). The methods used in the study at hand 
followed closely with the previous study’s methodology.  After recruiting 58 participants, 
31 obese, non-diabetic participants between the ages of 18 and 50 completed a 16-week 
double-blind study assessing the effects of Xanthigen supplementation on body 
composition, serum lipoprotein levels, and liver enzymes. Participation was open to 
males and females in the Hattiesburg area who met the following criteria: between ages 
18 and 50, pre-menopausal, qualify as being obese (BMI of greater than 30 kg/m2), must 
not be pregnant, must not have any known metabolic disorders, must not have taken any 
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thyroid, hyperlipidemic, hypoglycemic, anti-hypertensive, androgenic medications, or 
nutritional supplements known to influence fat metabolism within the past six month, 
must not have had a history of excessive alcoholic consumption. Participants were 
recruited from USM and the Hattiesburg area via word-of-mouth, email announcements, 
and online postings. All data collection was completed by the lead investigator or 
research assistants in the USM Laboratory of Applied Physiology.  
 After recruiting participants, they were separated into two experimental groups: a 
placebo group and a Xanthigen supplement group. Participants were grouped according 
to gender, age, and body fat percentage before being placed into either the placebo or 
Xanthigen groups using a randomized, double-blind procedure. To uphold the integrity of 
the double-blind aspect of this study, placebo capsules were packaged identically to the 
Xanthigen capsule, but were instead filled with 200 mg extra virgin olive oil. Xanthigen 
capsules were comprised of a combination of 100 mg of pomegranate seed oil and 100 
mg of brown seaweed extract with 0.8 mg of fucoxanthin.  
 Participants were first familiarized with the purpose, design, risks, and benefits 
associated with the study. After any questions were answered by the lead investigator or 
research assistants, an Informed Consent form and medical history questionnaire were 
completed by the participants. At the initial testing session (T1) research assistants 
assessed baseline body mass, height,  blood pressure, waist circumference, total body 
water (via bioelectrical impedance analysis), REE, and body composition (via Dual 
Energy X-ray Absorptiometry). The first samples of blood were also drawn by the lead 
investigator at this time. Blood was drawn the morning after an overnight fast using 
standard phlebotomy techniques. Serum samples were left standing at room temperature 
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for 10 minutes before being centrifuged. At the conclusion of T1, participants were 
randomly divided into placebo or supplement groups according to gender, age and body 
fat percentage.  
 Upon the conclusion of T1, participants were given dietary counseling concerning 
supplementation and the required standardized diet by a dietician. Two weeks of 
supplements were handed out at this time with directions instructing the participant to 
take their particular pills three times per day at 15-30 minutes prior to mealtime. 
Participants were placed on standardized diets throughout the 16-week study. A diet 
based on the Dietary Exchange Program was used to allow participants some freedom in 
their dietary choices, but still maintain a constant caloric intake. Caloric intake was 
determined according to each participant’s resting energy expenditure. Because of this 
freedom, participants were required to turn in four-day food logs every two weeks. 
Additional dietary counseling was provided if participants were found to be struggling 
with compliance or have additional questions concerning their diets. To encourage 
participants’ continued participation in the study, participants were only given two 
weeks’ worth of supplement upon each visit.  
 Testing session 2-5 (T2-5) occurred during weeks four through 16. Data 
collecting sessions occurred every four weeks throughout the study, although participants 
were still required to pick-up their next set of supplements and drop off food journals 
every two weeks. During testing sessions, participants reported to the Laboratory of 
Applied Physiology to have body mass, blood pressure, waist circumference, total body 
water, body composition, and REE assessed by research assistants. Another blood sample 
was also taken by the lead investigator upon each of these visits. Serum levels of 
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triglycerides, HDL, LDL, total cholesterol, glucose, AST, and ALT were assessed by 
medical technologists at the USM Health Services Clinic.  
 During each testing session, multiple tests were conducted. Each of these tests had 
a very specific procedure. First, the anthropometric measurements such as total body 
mass and waist circumference were performed using a standard digital scale (Ohaus 
Champ II) and standard anthropometric measurements, respectively (Pollock, Jackson, 
1984). These measures were collected and recorded by research assistants. Total body 
water was measured using bioelectrical impedance analysis (BIA; Tanita TBF-310GS). 
Percent body fat, fat mass, and fat-free mass were determined using dual energy X-ray 
absorptiometry (DEXA; GE Lunar Prodigy), and conducted by research assistants. 
Resting energy expenditure (REE) was assessed using the Vyasis Vmax Encore 
metabolic cart. Through the use of a transparent canopy connected to a gas mixing 
chamber, metabolic measurements were taken. To obtain these measurements, 
participants remained in a supine position for approximately 25 minutes without falling 
asleep. During these 25 minutes, respired gases were analyzed and oxygen uptake and 
carbon dioxide production was measured. These measurements were then used to 
calculate the participants’ REE and respiratory quotient (RQ). To assure that the 
combination of diet, exercise, and supplementation were safe, hemodynamic measures 
were taken and recorded during each session. Both blood pressure and heart rate were 
taken twice  while resting with an automated blood pressure monitor (Omron HEM 
907XL) and the average of the two results recorded by the research assistant.  
 As previously mentioned, participants were required to keep four-day food 
journals every two weeks. Dietary records were collected and entered into dietary 
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assessment software by research assistants. Finally, records were analyzed using the Food 
Processor dietary assessment software program (ESHA Research, Inc., Salem, OR).  
 Blood samples taken by the lead investigator during T1-T5 were drawn using 
standard sterile venipuncture technique. Samples were taken from the antecubital vein 
using standard phlebotomy procedures. Samples were taken only by the primary 
researcher or phlebotomists at the USM Health Services Center. Gloves and other safety 
equipment were always used when taking and handling blood samples. To obtain 
samples, participants were seated in a chair and had their arms cleaned with a sterile 
alcohol wipe and sterile gauze. A standard rubber tourniquet was placed on the upper arm 
and was tightened enough to slightly indent the arm, but not cause discomfort to the 
participant. After palpating the vein, a twenty-two gauge sterile needle attached to a 
vacutainer holder was inserted into the vein using standard procedure. Two serum 
separator tubes were subsequently inserted into the vacutainer holder. After collecting 
both samples, the needle and holder were removed. Needles were disposed of as 
hazardous waste in a plastic sharps container. The site of needle entry was promptly 
cleaned and pressure was applied using gauze to ensure proper clotting. All blood 
collection tubes were labeled and placed in their respective racks. Properly trained and 
clothed technicians, including research assistants, centrifuged the serum and plasma 
samples, transferred the samples into storage containers, and stored them at -80oC for 
later analysis. The USM Health Services Clinic ran a standard chemistry panel.  
 To determine the side effects of Xanthigen supplementation, participants were 
given surveys to complete during each testing session. Questionnaires were confidentially 
administered. Participants were asked to report whether their placebo or Xanthigen 
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supplement was tolerated, whether supplementation protocol was followed, and whether 
any medical problems or symptoms were encountered throughout the study.  
 Finally, the data were analyzed by the lead investigator using SPSS for Windows 
Version 17 software. Multivariate, repeated measures analyses of variance (MANOVAs) 
were used to assess BMI, body composition, REE, lipid markers, and liver function 
markers in a time versus supplement fashion. For further breakdown, separate, univariate 
ANOVAs were performed to assess the main effects of the experiment. To be considered 
significantly different, the probability of Type I error must be 0.05 or less. If a significant 
difference was found between variables, Tukey’s honestly significant differences post-
hoc procedures was performed.   
Chapter 4: Results 
Demographic Data 
 Demographic data for Xanthigen and placebo groups are presented in Table 1 
below. Upon baseline measures, there were no significant differences in age, body mass, 
BMI, or body fat percentage. This indicates that the matching and randomization based 
on these measures was successful.  




Body Composition   
Table 2 summarizes the changes seen in body composition, measured by DEXA, 
after the 16-week protocol was completed. Multivariate ANOVA indicated no significant 
main effects for time (p = 0.396), between group (p = 0.858), or group*time interaction 
effect (p = 0.897). Although most participants successfully lost weight, body fat 
percentage did not decrease in a similar fashion. Because body fat percentage did not 
decrease as weight was lost, it was assumed that weight loss was due to a combination of 
the loss of fat mass as well as lean mass. These findings are not consistent with the 
findings of Abidov and colleagues.  
Table 2: Body composition changes after the 16 week intervention† 
 
Serum Lipids  
 Table 3 summarizes the observed changes in serum lipids over 16 weeks. 
Multivariate ANOVA revealed a significant main effect for time (p = 0.043), but no 
between group (p = 0.816) or group*time interaction effect (p = 0.201). After the 
completion of a univariate analysis, it was determined that no significant changes were 
found. This being said, there was a trend for decreased triglycerides (132 ±90 mg/dL to 
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101 ± 58 in Xanthigen versus 138 ± 86 mg/dL to 133 ± 79 in placebo). HDL levels did 
increase by 9.5% (from 42±9 to 46±8) in the Xanthigen group and by 6.8% in the placebo 
group (44±12 mg/dL to 47±12 mg/dL). On the other hand, LDL levels decreased 8.1% 
(111±29 mg/dL to 102±25 mg/dL) in the placebo group, but actually increased 8.3% 
(109±37 mg/dL to 118±36 mg/dL) in the Xanthigen group. Total cholesterol also 
decreased in the placebo group (183±30 mg/dL to 175±30 mg/dL) by 4.4%, but increased 
in the Xanthigen group (177±34 mg/dL to 178±40 mg/dL) by 0.6%.  
  Table 3: Changes in serum lipids after the 16 week intervention† 
 
Serum Markers of the Metabolic Syndrome and Hepatic Enzyme Levels   
Table 4 summarizes the observed changes in markers of liver and kidney 
function. Multivariate ANOVA revealed a significant main effect for time (p < 0.001), 
but no between group (p = 0.327) or group*time interaction effect (p = 0.136). Univariate 
analysis revealed a significant decrease in ALP (p = 0.001), ALT (p = 0.021) and a trend 
for a decrease in AST (p = 0.062). Both groups showed a small decrease in ALP levels 
over 16-weeks, although the Xanthigen group showed larger decreases (-7.8% versus       
-5.5%, respectively). This indicated a significant change over time. AST levels decreased 
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in both groups as well. The Xanthigen group decreased from 26 ± 16 U/L to 22 ± 13 U/L 
(-15.4% change), while the placebo group decreased from 19 ± 5 U/L to 16 ± 7 U/L (-
15.8% change). While decreases were seen in both, these decreases were not considered 
significant. Like AST, ALT levels significantly decreased over 16 weeks. Xanthigen 
group decreased from 31 ± 27 U/L to 20 ± 8 U/L, indicating a -35.5% change. The 
placebo group decreased from 21 ± 7 U/L to 18 ± 12 U/L, indicating a -14.3% change.  
Multivariate ANOVA revealed no significant main effects for time (p = 0.066), 
between group (p = 0.249), or group*time interaction effect (p = 0.966) for total 
bilirubin, total protein, or albumin. Baseline levels of creatinine and blood urea nitrogen 
(BUN) were significantly higher in the Xanthigen group than placebo at baseline, so 
these variables were analyzed as delta changes from baseline. This analysis revealed a 
significant main effect for time (p = 0.001), but no between group (p = 0.878) or 
group*time interaction effect (p = 0.881). In the Xanthigen group, there was no change in 
total bilirubin content (0.7 ± 0.4 to 0.7 ± 0.4 mg/dL), but the placebo group saw a -14.3% 
change (0.7 ± 0.2 mg/dL to 0.6 ± 0.3 mg/dL). Both groups saw a decrease in creatinine – 
-10.0% in the Xanthigen group (1.0 ± 0.1 mg/dL to 0.9 ± 0.2 mg/dL) and -11.1% in the 
placebo group (0.9 ± 0.1 mg/dL to 0.8 ± 0.2 mg/dL). Blood urea nitrogen (BUN) did not 
change in the Xanthigen group (14 ± 4 mg/dL to 14 ± 3 mg/dL), but increased in the 
placebo group (11 ± 2 mg/dL to 12 ± 3 mg/dL). Total protein decreased in both groups as 
well, -4.2% in Xanthigen (7.1 ± 0.4 g/dL to 6.8 ±0.4 g/dL) and -2.9% in the placebo 
group (7.0 ± 0.3 g/dL to 6.8 ± 0.3 g/dL). While albumin did not change in the Xanthigen 
group (4.5 ± 0.4 g/dL to 4.5 ± 0.4 g/dL), albumin levels increased in the placebo group by 
2.3% (4.3 ± 0.4 g/dL to 4.4 ± 0.3 g/dL).  
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Table 4: Changes in serum markers of liver and kidney function after 16 weeks
 
 
Chapter 5: Discussion 
When comparing the current study’s results to results from the Abidov study 
(2010), there are some obvious differences. The Abidov study saw significant changes in 
many areas that the current study did not. These differences are the likely result of the 
small sample size of the current study and the large standard deviations presented with 
these variables. Other variations in study design that could have attributed to these 
different results involve the inclusion of obese men in the participant pool and not using a 
standardized 1800 kcal diet, but instead individualizing participants’ caloric intake based 
on their specific REE. 
 One of the most obvious differences between the current study and the Abidov 
study (2010) is the change in body mass. Specifically, the Abidov study participants saw 
a significant reduction in body mass after completing their 16-week intervention. In the 
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current study, as a whole, participants significantly reduced their body mass, but this 
reduction was not significantly greater in the Xanthigen group as it was with the Abidov 
study. It is probable that this inconsistency is due to the small sample size of the current 
study and the different diet criteria. Abidov strictly controlled the caloric intake of the 
participants to 1800 kcals; since the current study included both male and female 
participants, their diet was individualized based on their specific REE. Moreover, these 
participants were only provided with dietary guidelines and biweekly monitoring, while 
the previous study provided them with every meal.  
 Similar to body composition, there were inconsistencies between the Abidov 
study (2010) and current study when examining changes in liver enzymes. Abidov and 
colleagues saw significant reductions in ALT and AST with Xanthigen, but did not 
investigate ALP. The current study showed significant declines in ALT and ALP overall, 
but not as a result of Xanthigen. The current study also did not demonstrate a significant 
change regarding AST either. Again, these differences are apparently due to the small 
sample size of the current study and the large standard deviations. 
 The Abidov et al. (2010) study did not report cholesterol levels, but other lipids 
were reported. Much like the Abidov study, triglyceride levels in the current study 
decreased. This being said, the triglyceride levels in the current study dropped much 
more than levels in the Abidov study. It is common to see HDL levels increase, while 
LDL levels and triglycerides decrease with weight loss. It is probable that weight loss 
produced the lipid improvements, rather than Xanthigen supplementation.    
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 While the Abidov study did not take into account kidney function markers, the 
current study did. Although there were no significant changes between groups, there were 
significant changes from baseline levels. The most important information gathered from 
these measures was that these markers remained within safe and normal limits and were 
unaffected by the Xanthigen supplementation.  
Conclusion  
Overall, Xanthigen supplementation did not produce the desired effects. Although 
the Xanthigen group did see weight loss and slight improvements in serum markers, the 
placebo group saw many of the same results, indicating that it was not necessarily the 
Xanthigen supplementation that created the results seen. While this study did cover more 
bases than previous studies regarding this supplement, there are some improvements that 
could have been made.  One key aspect for improvement would be to more carefully 
monitor the diets of participants. Another way to improve the study would be to expand 
the sample size of the study. Future studies on Xanthigen supplementation may consider 
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